Medical Oncology

Uzm. Dr. Aslı Geçgel

Doctor and researcher Kartal Dr. Lütfi Kırdar Şehir Hastanesi İstanbul
Breast NeoplasmsMelanoma
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Breast Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Melanoma 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
  • Area of workBreast NeoplasmsExtracted from 3 publications · Model version —From source
  • Publications47 publicationsOpenAlex, Europe PMCFrom source
  • ORCID0000-0001-6942-9858ORCIDFrom source
  • Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1480911/doktorlarimiz.html#asli-gecgelsaglik.gov.tr

Scientific work

Publications on Breast Neoplasms

47 publications

  1. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex

  2. Evaluation of Olaparib Efficacy Following CDK4/6 Inhibitor Therapy in BRCA-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Turkish Oncology Group (TOG) Study

    Targeted Oncology, 2026

    DOI 10.1007/s11523-026-01261-w PMID 42907609 Source: OpenAlex

  3. Treatment Outcomes and Toxicity of Cisplatin–Etoposide-Based Regimens and Carboplatin–Paclitaxel as Adjuvant Chemotherapy for Ovarian Adult Granulosa Cell Tumors: A Multicenter Retrospective Cohort Study

    Cancers, 2026

    DOI 10.3390/cancers18182910 PMID 42794877 Open-access full textSource: OpenAlex

  4. Clinical Outcomes of Lenvatinib-Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort

    Clinical Medicine Insights. Oncology, 2026

    DOI 10.1177/11795549261472694 PMID 42523965 Open-access full textSource: Europe PMC

  5. Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?

    Future oncology (London, England), 2026

    DOI 10.1080/14796694.2026.2746184 PMID 42844909 Source: Europe PMC

  6. Prognostic Significance of Pretreatment Mean Platelet Volume in Patients with Recurrent or De Novo Metastatic Breast Cancer: A Single-Center Retrospective Study

    Breast cancer (Dove Medical Press), 2026

    DOI 10.2147/bctt.s629176 PMID 42518661 Open-access full textSource: Europe PMC

  7. A hidden danger in cancer patients: intestinal parasites

    Turkish journal of medical sciences, 2026

    DOI 10.55730/1300-0144.6370 PMID 42677300 Open-access full textSource: Europe PMC

  8. Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer

    Frontiers in Nutrition, 2026

    DOI 10.3389/fnut.2026.1745718 PMID 41783818 3 citations (OpenAlex) Open-access full textSource: OpenAlex

  9. Survival Patterns in Early-onset Colorectal Cancer Receiving Adjuvant Capecitabine Based Therapy

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-11-8 Open-access full textSource: OpenAlex

  10. Predicting 10-year survival in early and locally advanced breast cancer: prognostic value of nutritional status and body composition

    Nutrition, 2026

    DOI 10.1016/j.nut.2026.113133 PMID 41775036 Source: OpenAlex

View all 47 publications